Anticoagulant treatment and COVID-19
Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi · 2022
DOI: 10.34087/cbusbed.1007918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 2022. Verfasst von İbrahim Halil ÖZDEMIR und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: yok.
Abstract (Originalsprache)
Objective
In this study, we aimed to examine the effect of atrial fibrillation (AF) on mortality in COVID-19 patients and the risk scores that can be used in determining risky AF patients. In addition, we aimed to examine the place of oral anticoagulant use in treatment. Materials and Methods: Records of patients diagnosed with COVID-19 were retrospectively reviewed. Among these patients, 48 patients with a diagnosis of AF were identified. Intensive care need, mortality, CHA2DS2VASC and HAS-BLED scores of the patients were recorded. CRP and D-Dimer levels were recorded. Oral anticoagulant treatments used by the patients were recorded.
Results
The CHA2DS2VASC (intensive care: 4,50±1,41, internal medicine service: 2,50±1,05, p
Förderung
- yok
Zitieren
APA
ÖZDEMIR, İ. H., ÖZEN, M. B., & GÜNDÜZ, R. (2022). Anticoagulant treatment and COVID-19. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. https://doi.org/10.34087/cbusbed.1007918
Vancouver
ÖZDEMIR İH, ÖZEN MB, GÜNDÜZ R. Anticoagulant treatment and COVID-19. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2022. doi:10.34087/cbusbed.1007918
BibTeX
@article{ZDEMIR2022,
author = {ÖZDEMIR, İbrahim Halil and ÖZEN, Mehmet Burak and GÜNDÜZ, Ramazan},
title = {Anticoagulant treatment and COVID-19},
journal = {Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi},
year = {2022},
doi = {10.34087/cbusbed.1007918}
}
EUVIMED